Michael Cherny
Stock Analyst at B of A Securities
(4.31)
# 342
Out of 5,182 analysts
121
Total ratings
59.55%
Success rate
13.52%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MCK McKesson | Maintains: Buy | $1,040 → $1,000 | $873.43 | +14.49% | 16 | Apr 6, 2026 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $18 → $25 | $19.75 | +26.58% | 12 | Mar 16, 2026 | |
| TDOC Teladoc Health | Maintains: Market Perform | $8.5 → $5.5 | $5.25 | +4.76% | 2 | Feb 26, 2026 | |
| HSIC Henry Schein | Maintains: Market Perform | $75 → $87 | $75.62 | +15.05% | 3 | Feb 24, 2026 | |
| ACH Accendra Health | Maintains: Market Perform | $3 → $2.75 | $2.63 | +4.56% | 1 | Feb 20, 2026 | |
| XRAY DENTSPLY SIRONA | Upgrades: Buy | $13 → $17 | $11.86 | +43.34% | 9 | Feb 19, 2026 | |
| MEDP Medpace Holdings | Maintains: Market Perform | $575 → $485 | $501.50 | -3.29% | 2 | Feb 11, 2026 | |
| CVS CVS Health | Maintains: Buy | $100 → $95 | $78.84 | +20.50% | 12 | Jan 27, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $45.69 | +5.06% | 1 | Jan 12, 2026 | |
| CERT Certara | Upgrades: Outperform | $13 | $5.41 | +140.30% | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $203 → $210 | $197.82 | +6.16% | 3 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $188 → $186 | $215.80 | -13.81% | 13 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $28 | $16.53 | +69.39% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $3 | $1.15 | +162.01% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $23 | $26.67 | -13.76% | 11 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $90 | $21.16 | +325.33% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $174.53 | +60.43% | 3 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $168.98 | +46.76% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $106.72 | +138.94% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $322.46 | -14.72% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $273.26 | -4.85% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $2.16 | +270.37% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $1.05 | +4,900.00% | 2 | Jan 5, 2022 |
McKesson
Apr 6, 2026
Maintains: Buy
Price Target: $1,040 → $1,000
Current: $873.43
Upside: +14.49%
Hims & Hers Health
Mar 16, 2026
Maintains: Market Perform
Price Target: $18 → $25
Current: $19.75
Upside: +26.58%
Teladoc Health
Feb 26, 2026
Maintains: Market Perform
Price Target: $8.5 → $5.5
Current: $5.25
Upside: +4.76%
Henry Schein
Feb 24, 2026
Maintains: Market Perform
Price Target: $75 → $87
Current: $75.62
Upside: +15.05%
Accendra Health
Feb 20, 2026
Maintains: Market Perform
Price Target: $3 → $2.75
Current: $2.63
Upside: +4.56%
DENTSPLY SIRONA
Feb 19, 2026
Upgrades: Buy
Price Target: $13 → $17
Current: $11.86
Upside: +43.34%
Medpace Holdings
Feb 11, 2026
Maintains: Market Perform
Price Target: $575 → $485
Current: $501.50
Upside: -3.29%
CVS Health
Jan 27, 2026
Maintains: Buy
Price Target: $100 → $95
Current: $78.84
Upside: +20.50%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $45.69
Upside: +5.06%
Certara
Jan 6, 2026
Upgrades: Outperform
Price Target: $13
Current: $5.41
Upside: +140.30%
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $197.82
Upside: +6.16%
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $215.80
Upside: -13.81%
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $16.53
Upside: +69.39%
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.15
Upside: +162.01%
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $26.67
Upside: -13.76%
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $21.16
Upside: +325.33%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $174.53
Upside: +60.43%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $168.98
Upside: +46.76%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $106.72
Upside: +138.94%
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $322.46
Upside: -14.72%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $273.26
Upside: -4.85%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $2.16
Upside: +270.37%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $1.05
Upside: +4,900.00%